The Pharma Letter: Why ADC development needs new level of bioconjugation expertise

Antibody-drug conjugates (ADCs) have moved from a promising concept to one of the most actively developed drug classes in oncology. Behind that progress lies a manufacturing challenge that is becoming more demanding by the year.

The global ADC market was valued at around $14.75 billion in 2024 and is projected to reach approximately $36 billion by 2034, driven by an expanding clinical pipeline and growing confidence in ADCs as a precision oncology tool.

Click Here to Access the Article